Do Medical Part B increase or decrease the prices of physician-administrative drugs relative to the doctors-administered drugs covered by private insurance? This question is a paper that is to respond to Aquatela, Ericsson and Stark (2023).
Before we answer that question, we need to understand first How Part B works, how doctors are reimbursed, and how much the medicine beneficiaries have to pay,
“Part B has a purchase-and-bill policy, in which doctors buy drugs (either on their own, or as part of a group purchasing organization) … The provider pays a price to the producer who is an average to manufacture an average selling price (ASP). The provider is usually compensated for aspa-sp.a.
How do writers identify the effects of Part B on drug prices?
The variation of our identity comes from drugs that are exposed to less or less part B: part of the expenditure for a drug that comes through the Medicare Part B, unlike private insurers. A similar research design is used by Yurukoglu et al. (2017)…
What data do they use?
We create a sample of prices and medicare market shares for physician-administered drugs spread in 2006 through 2019. Our unit of analysis is a drug-coastter, where drugs are specificly identified by the health care process coding system (HCPCS) code. We combine data from three sources: pricing files, collected medicare claims, and unaccounted collection of Truven Marketskain…. We receive the total drug payments of the medicine from the CMS Part B National Summary Data File, including the annual data on the payment collected for the Aggregate Code for each HCPCs code.
Using this approach, what are the results of authors?
The price increases in the drugs that come in contact with the medicare are low. The middle part B is a 10% lower price after 3 years after 3 years, compared to a medium approved molecules with a drug with a drug with a drug, with a large impact for a middle approved molecules.
You can read full paper Here,
